Table 1.
Hospital Readmission Rates and Average Readmission Costs for Medication-Based Patient Cohorts: 1999–2010. The readmission percentage is found by dividing the number readmitted to the hospital by the total number of patients who experienced an initial diabetes-related hospitalization. Readmission cost is expressed in 2010 U.S. dollars
| Patient Cohort | Total number (SE) | Number not readmitted (SE) | Number readmitted (SE) | Readmission percentage | Mean readmission cost (SE) |
|---|---|---|---|---|---|
| All Patients | 13,537,803 (519,634) | 10,959,266 (451,218) | 2,578,538 (198,384) | 19.1 | $8,814 ($580) |
| All SU Patients a | 7,871,912 (368,351) | 6,204,869 (326,273) | 1,667,043 (153,735) | 21.2 | $9,204 ($769) |
| SU (SU monotherapy) b | 3,217,089 (235,951) | 2,470,510 (194,884) | 746,579 (106,554) | 23.2 | $11,148 ($1,558) |
| SU+ (other AHA) | 4,654,823 (274,495) | 3,734,359 (247,494) | 920,464 (113,487) | 19.8 | $7,624 ($412) |
| All Other Oral AHA Patients a | 5,665,891 (291,467) | 4,754,397 (256,821) | 911,495 (108,690) | 16.1 | $8,098 ($737) |
| noSU (monotherapy with non-SU AHA) b | 5,488,379 (288,154) | 4,606,396 (254,357) | 881,984 (107,289) | 16.1 | $7,673 ($763) |
| noSU+ (> 1 non-SU AHA) | 177,512 (na) | 148,001 (na) | 29,511 (na) | 16.6 | $20,772 (na) |
SE standard error
na not available due to too low raw cell count
SU sulfonylurea
AHA antihyperglycemic agent
a In a comparison between all SU (SU and SU+) patients and all other oral AHA patients, the relevant p-value for readmission rates was 0.017
b In a comparison between SU patients and noSU monotherapy patients, the relevant p-value for readmission rates was 0.003